The Legal Issue
The core issue before the Supreme Court was the exorbitant cost of essential medicines, particularly cancer drugs, which rendered them inaccessible to a significant portion of the population. While there was no specific statutory challenge mentioned, the Court was exercising its inherent jurisdiction to address a matter of public interest concerning the right to health and access to life-saving medication. The Court's consistent questioning aimed to compel the Union Government to take concrete steps to regulate drug prices and ensure affordability.
Court's Reasoning
Although the LiveLaw report does not detail a formal judgment or specific legal reasoning, it highlights the Supreme Court's persistent and probing questions to the Union Government regarding the high trade margins on cancer drugs. The Court's stance implicitly recognized the fundamental right to health and the State's obligation to ensure access to essential healthcare, including affordable medicines. By repeatedly questioning the government's inaction and the rationale behind unchecked margins, the Court effectively pushed the executive to formulate a policy solution. The government's decision to cap margins at 30% was a direct response to this judicial pressure, indicating an acknowledgment of the Court's concerns regarding public welfare.
Why It Matters
This development is significant as it demonstrates the Supreme Court's proactive role in safeguarding public health and affordability of essential services, even in the absence of a direct statutory mandate. The decision to cap trade margins on cancer drugs will have a tangible positive impact on patients, making life-saving treatments more accessible and affordable. For advocates, this serves as a precedent where judicial intervention has led to executive policy changes benefiting the public. Furthermore, the Court's query about extending similar caps to 'all medicines' signals a potential future direction for broader drug price regulation, which could have far-reaching implications for the pharmaceutical industry and public health policy in India.